Results 281 to 290 of about 41,710 (302)

Dipeptidyl peptidase-4 inhibitors: sensitivity markers

Biotechnology. Theory and practice, 2017
A.N. Iskakova, A.M. Aitkulova, N.S. Sikhayeva, A.A. Romanova, L. Maratkyzy, Zh. A. Akanov, E.V. Zholdybayeva   +6 more
openaire   +1 more source

Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia–reperfusion rat heart

Diabetes and Vascular Disease Research, 2014
Kroekkiat Chinda, Nipon Chattipakorn
exaly  

Dipeptidyl-peptidase-4-inhibitors

Reactions Weekly
openaire   +2 more sources

Dipeptidyl peptidase‐4 inhibitors and cardiovascular safety

Medical Journal of Australia, 2014
openaire   +2 more sources

Analyzing a dipeptide library to identify human dipeptidyl peptidase IV inhibitor

Food Chemistry, 2015
Keisuke Ito, Sohei Ito, Yasuaki Kawarasaki   +2 more
exaly  

Dipeptidyl peptidase-4 inhibitors/metformin

Reactions Weekly, 2018
openaire   +1 more source

Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits

Journal of the American Heart Association, 2017
Ning Jiang, Xue Liang, Gary Tse
exaly  

A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice

Journal of the American College of Cardiology, 2012
Taishi Nakamura, Koichi Kaikita, Yukio Fujiwara   +2 more
exaly  

Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions

Circulation, 2012
Yasuko K Bando, Akihiro Hirashiki, Toyoaki Murohara   +2 more
exaly  

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion, 2009
Jane Eb Reusch
exaly